In 2018, Johnson & Johnson embarked on a mission to revolutionize the way blood clots are studied. Their goal was to determine the impact of various clot characteristics such as size, composition, and density on patient outcomes, as well as how two of their medical devices performed in clot removal. To achieve this, they conducted a study that enrolled 1,000 stroke patients at 36 clinical trial sites worldwide and analyzed actual blood clots removed from stroke patients.
The study, known as the Excellent Registry, is the largest acute ischemic stroke registry globally. It collects patient data, imaging, and clot information on a per-pass basis, with independent evaluators reviewing the data. This initiative underscores Johnson & Johnson’s commitment to innovation in advancing stroke care. With alarming statistics that every 40 seconds someone in the United States has a stroke and every 3.5 minutes someone dies from one, Johnson & Johnson’s dedication to improving stroke care is crucial.
For more information from Johnson & Johnson, click here.